Cargando…

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

BACKGROUND: It is well known that genetic alternation of epidermal growth factor receptor (EGFR) plays critical roles in tumorgenesis of lung cancer and can predict outcome of non-small-cell lung cancer treatment, especially the EGFR tyrosine-kinase inhibitors (EGFR-TKIs) therapy. However, it is unc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jian, Wang, Yuyan, Duan, Jianchun, Bai, Hua, Wang, Zhijie, Wei, Lai, Zhao, Jun, Zhuo, Minglei, Wang, Shuhang, Yang, Lu, An, Tongtong, Wu, Meina, Wang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524045/ https://www.ncbi.nlm.nih.gov/pubmed/23009178 http://dx.doi.org/10.1186/1756-9966-31-80

Ejemplares similares

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
por: Wang, Zhijie, et al.
Publicado: (2014)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
por: Wang, Shuhang, et al.
Publicado: (2015)

Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer
por: Wang, Shuhang, et al.
Publicado: (2013)

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer
por: Bai, Hua, et al.
Publicado: (2013)

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung
por: Duan, Jianchun, et al.
Publicado: (2015)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma
por: Wang, Shuhang, et al.
Publicado: (2020)

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer
por: Yang, Xue, et al.
Publicado: (2016)

Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival
por: Majchrzak-Celińska, Aleksandra, et al.
Publicado: (2015)

Early Determination of the Periodontal Domain by the Wnt-Antagonist Frzb/Sfrp3
por: Mitsiadis, Thimios A., et al.
Publicado: (2017)

The role of dexamethasone in mediating the contradictory effects of Wnt antagonists SFRP2 and SFRP3 on human hair follicle growth
por: Hamida, Ons Ben, et al.
Publicado: (2023)

Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer
por: Lv, Chunxin, et al.
Publicado: (2018)

Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer
por: Duan, Jianchun, et al.
Publicado: (2017)

The Wnt antagonist sFRP1 is downregulated in premalignant large bowel adenomas
por: Caldwell, G M, et al.
Publicado: (2006)

The Wnt Antagonist sFRP1 as a Favorable Prognosticator in Human Biliary Tract Carcinoma
por: Kang, Pengcheng, et al.
Publicado: (2014)

Stemness, Pluripotentiality, and Wnt Antagonism: sFRP4, a Wnt antagonist Mediates Pluripotency and Stemness in Glioblastoma
por: Bhuvanalakshmi, Gurubharathi, et al.
Publicado: (2018)

Efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel for non‐small cell lung cancer patients who have failed at least two prior systemic treatments
por: Duan, Jianchun, et al.
Publicado: (2017)

Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma
por: Zhong, Jia, et al.
Publicado: (2018)

Hyperactivated Wnt-β-catenin signaling in the absence of sFRP1 and sFRP5 disrupts trophoblast differentiation through repression of Ascl2
por: Bao, Haili, et al.
Publicado: (2020)

Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience
por: Wang, Lu, et al.
Publicado: (2020)

iPSC-Derived Glioblastoma Cells Have Enhanced Stemness Wnt/β-Catenin Activity Which Is Negatively Regulated by Wnt Antagonist sFRP4
por: Yasmin, Ishmat Ara, et al.
Publicado: (2023)

Radiomic Feature-Based Nomogram: A Novel Technique to Predict EGFR-Activating Mutations for EGFR Tyrosin Kinase Inhibitor Therapy
por: Weng, Qiaoyou, et al.
Publicado: (2021)

Hypoxia‐inducible factor‐1α and nuclear factor‐κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non‐small‐cell lung cancer cells
por: Guo, Rong, et al.
Publicado: (2019)

SFRP5 inhibits the migration and invasion of melanoma cells through Wnt signaling pathway
por: Chen, Yangmei, et al.
Publicado: (2018)

GEC-derived SFRP5 Inhibits Wnt5a-Induced Macrophage Chemotaxis and Activation
por: Zhao, Chenghai, et al.
Publicado: (2014)

Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma
por: Sremac, Maja, et al.
Publicado: (2021)

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis
por: Zhao, Zhe, et al.
Publicado: (2020)

SFRP2 enhances the osteogenic differentiation of apical papilla stem cells by antagonizing the canonical WNT pathway
por: Jin, Luyuan, et al.
Publicado: (2017)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
por: Shi, Xuefei, et al.
Publicado: (2020)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
por: Wang, Wenxian, et al.
Publicado: (2016)

Decreased expression of SFRP2 promotes development of the pituitary corticotroph adenoma by upregulating Wnt signaling
por: Ren, Jie, et al.
Publicado: (2018)

High‐fidelity of non‐small cell lung cancer xenograft models derived from bronchoscopy‐guided biopsies
por: Fu, Shuai, et al.
Publicado: (2015)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

RASSF4 Overexpression Inhibits the Proliferation, Invasion, EMT, and Wnt Signaling Pathway in Osteosarcoma Cells
por: Zhang, Minglei, et al.
Publicado: (2017)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
por: Wang, Jun, et al.
Publicado: (2016)

An Overview of Ovarian Cancer: The Role of Cancer Stem Cells in Chemoresistance and a Precision Medicine Approach Targeting the Wnt Pathway with the Antagonist sFRP4
por: Varier, Lavanya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_osqb74fi38nh3it05d0de69sc0